Published in Ther Drug Monit on June 01, 1993
Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit (1995) 0.83
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
Pharmacokinetics of FK 506 in transplant patients. Transplant Proc (1991) 1.30
A whole blood FK 506 assay for the IMx analyzer. Transplant Proc (1991) 1.21
Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc (1991) 1.19
Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. Clin Chem (1992) 0.97
FK 506 assay past and present--characteristics of FK 506 ELISA. Transplant Proc (1991) 0.93
Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc (1991) 0.92
A combined HPLC-ELISA evaluation of FK 506 in transplant patients. Transplant Proc (1991) 0.87
High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc (1991) 0.84
Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood. Clin Chem (1992) 0.82
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Kidney transplantation under FK 506. JAMA (1990) 7.45
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
IMMUNOSUPPRESSION WITH FR 900506 FOR CANINE KIDNEY AND LIVER TRANSPLANTATION. Surg Res Commun (1987) 4.68
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Water metabolism in relation to the menstrual cycle. J Physiol (1937) 3.72
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet (1986) 3.53
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42
Components of histidine transport: histidine-binding proteins and hisP protein. Proc Natl Acad Sci U S A (1970) 3.39
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Factors in sexual-skin oedema. J Physiol (1938) 3.27
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Some Effects of Oestrin on the Menstrual Cycle of Baboons and Macaques. J Anat (1931) 3.13
The occurrence of an oestrogenic substance in the sexual skin of monkeys. Biochem J (1936) 3.06
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther (1985) 2.38
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol (1988) 2.21
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
How did Medicare's prospective payment system affect hospitals? N Engl J Med (1987) 2.05
Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96
Role of murein lipoprotein in morphogenesis of the bacterial division septum: phenotypic similarity of lkyD and lpo mutants. J Bacteriol (1978) 1.94
Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg (2000) 1.89
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Profits and fiscal pressure in the prospective payment system: their impacts on hospitals. Inquiry (1989) 1.85
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
Outcome of preimplantation genetic diagnosis of translocations. Fertil Steril (2000) 1.78
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
The Endocrine Control of the Prostate: (Section of Urology). Proc R Soc Med (1936) 1.77
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Small intestinal transplantation in humans with or without the colon. Transplantation (1994) 1.74
Medicaid managed care in thirteen states. Health Aff (Millwood) (1998) 1.71
Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm (1995) 1.69
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
Receipt of preventive health care services by lesbians. Am J Prev Med (2000) 1.67
EMG responses to maintain stance during multidirectional surface translations. J Neurophysiol (1998) 1.67
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67
Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis (1985) 1.61
The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60
PCR primers for human chromosomes: reagents for the rapid analysis of somatic cell hybrids. Genomics (1991) 1.58
Lesbians' sexual history with men: implications for taking a sexual history. Arch Intern Med (2000) 1.57
New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc (1991) 1.56
Cost of practice and geographic variation in Medicare fees. Health Aff (Millwood) (1989) 1.56
Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients. Transplant Proc (1985) 1.55
Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant (2006) 1.55
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant (2013) 1.54
Functional outcome of thoracolumbar burst fractures without neurological deficit. J Orthop Trauma (1996) 1.47
Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol (1989) 1.45
Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44
Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology (2000) 1.44
Confirming insurance coverage in a telephone survey: evidence from the National Survey of America's families. Inquiry (2000) 1.42
Intestinal transplantation at the University of Pittsburgh. Transplant Proc (1994) 1.42
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40
Control of stance during lateral and anterior/posterior surface translations. IEEE Trans Rehabil Eng (1998) 1.39
Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc (1988) 1.38
FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37
Abdominal multivisceral transplantation. Transplantation (1995) 1.37
Autopsy findings in a long-surviving liver recipient. N Engl J Med (1973) 1.36
Assay of FK 506 in plasma. Transplant Proc (1990) 1.32
Variation in the sensitivity of different species of monkeys to oestrin. J Physiol (1935) 1.32
Sensitivity of activated human lymphocytes to cyclosporine and its metabolites. Hum Immunol (1988) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos (1999) 1.30
Pharmacokinetics of FK 506 in transplant patients. Transplant Proc (1991) 1.30
The association of center performance evaluations and kidney transplant volume in the United States. Am J Transplant (2013) 1.28
Effect of stance width on multidirectional postural responses. J Neurophysiol (2001) 1.28
Excretion of cyclosporine and its metabolites in human bile. Transplant Proc (1986) 1.27
Successful sequential liver-kidney transplantation in a patient with performed lymphocytotoxic antibodies. Transplant Proc (1987) 1.25
Role of bile and bile salts on cyclosporine absorption in dogs. Transplant Proc (1987) 1.24
Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23
Postural orientation, equilibrium, and the spinal cord. Adv Neurol (1997) 1.21
Comparison of UW with other solutions for liver preservation in dogs. Clin Transplant (1989) 1.20
Adaptation of the walking pattern to uphill walking in normal and spinal-cord injured subjects. Exp Brain Res (1999) 1.20
Weight support and balance during perturbed stance in the chronic spinal cat. J Neurophysiol (1999) 1.20